Key points are not available for this paper at this time.
The results provide a clearer understanding of how to interpret BPRS total and percentage reduction scores in clinical trials with patients acutely ill with schizophrenia who are experiencing positive symptoms.
Leucht et al. (Fri,) studied this question.